OBJECTIVE： To provide reference for safe drug use of paclitaxel in clinic. METHODS： The literatures about anaphylactic shock induced by paclitaxel were retrieved from China Hospital Knowledge Database during 2006-2016. After screening literatures which met inclusion criteria， the literatures were analyzed statistically in respects of the distribution of patient’s gender and age， primary disease， distribution of occurrence time of anaphylactic shock， prophylactic drug use， route of administration and dosage， combined with chemotherapy drugs， prodromal clinical manifestations， first-aid measures and prognosis， etc. RESULTS： A total of 53 cases of anaphylactic shock induced by paclitaxel were included， among which there were 16 male and 37 female， aged 17-72 years； female patients over 40 year-old took up the highest proportion （30 cases， 56.60％）. The major primary diseases were lung cancer （15 cases， 28.30％）， breast cancer （12 cases， 22.64％） and ovarian cancer （11 cases， 20.75％）. Anaphylactic shock mainly occurred within 5 min after intravenous dripping （34 cases， 64.15％）. 45 cases （84.90％） received antiallergic prophylactic program before using paclitaxel； 53 patients were given intravenous dripping with single dose of 30-300 mg. Among 53 patients， 25 patients were given paclitaxel alone， and other patients were given paclitaxel combined with chemotherapy drugs. The prodromal clinical symptoms of anaphylactic shock mainly involved cardiovascular system（123 case time，36.07％）， skin and mucous membrane system（73 case time，21.41％） and respiratory system（67 case time，19.64％）. 2 patients （3.77％） died after rescue treatment. CONCLUSIONS： More attention must be paid to the occurrence of anaphylactic shock induced by paclitaxel.